Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.36 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.34 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL432112 | 0.82 | HDAC6 (0.37) | HDAC6HDAC1HDAC2DGAT1CA14 | |
| Hydrochloric Acid SCHEMBL5679482 | 0.80 | HDAC6 (0.36) | HDAC6HDAC1HDAC2DGAT1CA14 | |
| SCHEMBL1706932 | 0.79 | HDAC6 (0.38) | HDAC6HDAC1HDAC2DGAT1CA14 | |
| SCHEMBL1771686 | 0.79 | HDAC6 (0.38) | HDAC6HDAC1HDAC2DGAT1CA14 | |
| SCHEMBL28097176 | 0.77 | HDAC6 (0.37) | HDAC6HDAC1HDAC2DGAT1CA14 | |
| SCHEMBL13286079 | 0.77 | HDAC6 (0.37) | HDAC6HDAC1HDAC2DGAT1CA14 | |
| SCHEMBL29180397 | 0.76 | DGAT1 (0.37) | HDAC6HDAC1HDAC2DGAT1CA14 | |
| SCHEMBL8737769 | 0.76 | HDAC6 (0.39) | HDAC6HDAC1HDAC2DGAT1CA14 | |
| SCHEMBL10023648 | 0.75 | HDAC6 (0.36) | HDAC6HDAC1HDAC2DGAT1CA14 | |
| SCHEMBL2028779 | 0.75 | HDAC6 (0.36) | HDAC6HDAC1HDAC2DGAT1CA14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190202823-A1 | N-SULFONYLATED PYRAZOLO[3,4-b]PYRIDIN-6-CARBOXAMIDES AND METHOD OF USE | ABBVIE SARL (LU) | 2019-07-04 | — | — | US | disclosed |
| EP-3233849-A1 | HETEROARYLALKYLENE ARYL SULTAM DERIVATIVES AS RORc MODULATORS | F. Hoffmann-La Roche AG (CH) | 2017-10-25 | — | — | EP | disclosed |
| WO-2016096936-A1 | HETEROARYLALKYLENE ARYL SULTAM DERIVATIVES AS RORc MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2016-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190202823-A1 | N-SULFONYLATED PYRAZOLO[3,4-b]PYRIDIN-6-CARBOXAMIDES AND METHOD OF USE | CFTR, P2RY1, P2RX5 | HDAC6 956/4885HDAC1 2489/4885HDAC2 2033/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.